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Less exacerbations and sustained asthma control 12 months
after high altitude climate treatment for severe asthma
To the Editor,
Despite comprehensive asthma treatment guidelines and the avail-
ability of effective medication and promising new biologicals, man-
agement of patients with severe asthma is still challenging. Severe
uncontrolled asthma is a burden for patients and caregivers repre-
senting a major cause of disability, poor quality of life, and high
health resource utilization. Current international treatment guidelines
include referral for assessment in specialized asthma centers, evalua-
tion of the eligibility for biologicals, and non‐pharmacological add‐on
interventions, such as allergen avoidance measures and high altitude
climate treatment (HACT).1,2 HACT results in improvement of all
aspects of asthma control especially in adult patients with severe
asthma.3 HACT combines a 12‐week multidisciplinary treatment pro-
gram with environmental trigger avoidance in the alpine climate and
is provided throughout the year. It is unclear how long these treat-
ment effects are sustained, although it is known that some patients
have a long‐time advantage of HACT. Therefore, we evaluated the
long‐term effectiveness of HACT on exacerbations and asthma con-
trol in patients with severe asthma.
A prospective observational cohort study with a 12‐month fol-
low‐up period at sea level was carried out between 2008 and
2011.4 Four follow‐up study assessments consisting of question-
naires were planned for each patient at 0, 3, 6, and 12 months
after HACT. All patients provided written informed consent. The
study was approved by the institutional review board of the Aca-
demic Medical Centre of the University of Amsterdam and is reg-
istered at the Netherlands Trial Register NTR1277. Patients
included in the study were adults with uncontrolled asthma
despite using high doses of inhaled corticosteroids combined with
long‐acting bronchodilators for more than 1 year, who experienced
at least two severe exacerbations requiring a course of oral corti-
costeroids during the past year, or received maintenance oral cor-
ticosteroid therapy. The primary outcome of this study was the
change in exacerbation rate during the year after compared to the
year before admission to the Dutch Asthma Centre Davos,
Switzerland (altitude 1560 m). An exacerbation was defined as the
requirement for an oral steroid burst, based on pharmacy data.
Asthma‐related hospitalization was self‐reported by the patient.
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Secondary outcomes included use and dose of oral corticosteroids
during follow‐up, asthma control (ACQ), and asthma‐related quality
of life (AQLQ).
Hundred and eighty patients were asked to participate in the
study, and 101 patients (58%) completed the 12‐month follow‐up
period (Figure S1). The majority of patients were female, middle‐
aged, had multimorbidities and required chronic oral steroid treat-
ment (Table S1). Differences between those lost to follow up and
completers are shown in Table S2. Those lost to follow up were
significantly younger and had significantly higher ACQ scores at
discharge. A significant decrease in exacerbations (34% decrease)
and hospitalizations (36% decrease) was observed compared to
the year before HACT (Table 1). There was no change in the need
or amount of maintenance oral corticosteroid use at 12 months
before compared to 12 months after HACT (Table 1). There was a
decrease in ACQ from admission to 12 months after discharge,
the ACQ score at admission was median (IQR) 3.0 (1.37), at dis-
charge 1.0 (1.5), at follow‐up by 3 months 2.0 (2.0), at 6 months
2.0 (2.0), at 12 months 2.3 (2.0) (Figure 1A). There was an
increase in AQLQ score from admission with a median (IQR) 4.0
(1.22), to discharge 6.0 (1.1), at follow‐up by 3 months 5.2 (1.6),
at 6 months 5.1 (1.4), at 12 months 5.0 (1.6) (Figure 1B). After
twelve‐month follow‐up, there were statistically significant and
clinically relevant sustained improvements in ACQ and AQLQ com-
pared to baseline (P < 0.000).
Our study is the first to show a decrease in exacerbations and
sustained improvement in asthma control up to 12 months after
HACT in adult patients with uncontrolled severe asthma. However,
the observational study design makes it difficult to identify the
driving mechanism for the observed improvement. A characteristic
feature of HACT in the alpine climate of Davos is the absence of
most triggers. Triggers are known to stimulate and maintain airway
inflammation, and trigger avoidance (house dust mite, pollen, air
pollution) is recommended in treatment guidelines.5 We hypothe-
size that trigger avoidance through climate change to high altitude
can change the ongoing airway inflammation.4,6,7 In addition, the
extensive multidisciplinary treatment program including education
in trigger avoidance at home and optimization of adherence to
therapy will help to sustain the effect. The 12‐week multidisci-
plinary treatment program included a personalized exercise pro-
gram with various indoor and outdoor activities, optimization of
F IGURE 1 Asthma control and asthma‐related quality of life up to 12 mo after high altitude climate treatment. A, Asthma Control
Questionnaire (ACQ) scores at admission, discharge, 3‐, 6‐, and 12‐month follow‐up in 101 patients with severe asthma. Data are presented as
median (interquartile range). The dashed line indicates an ACQ score of 1.5. There is a clinically relevant difference of 0.7 between admission
and 12‐mo follow‐up. B, Asthma‐related Quality of Life Questionnaire (AQLQ) scores at admission, discharge, 3‐, 6‐, and 12‐month follow‐up in
101 patients with severe asthma. Data are presented as median (interquartile range). There is a clinically relevant difference of 1.0 between
admission and 12‐mo follow‐up
TABLE 1 Exacerbations, hospitalizations, and oral corticosteroid
use before and after high altitude treatment
Year
before
treatment
Year
after
treatment
%
decrease P‐value
Number of
exacerbations per
patient (pharmacy
data)
3 (4)
n = 97
2 (3)
n = 95
34 0.000
Number of
exacerbations per
patient (patient
reported)
5 (6) 2 (4)
n = 98
60 0.000
Number of hospitalized
patients
51 (50.5%) 28 (32%)
n = 87
36 0.014
Number of
hospitalizations
per patient
2 (2) 0.5 (2.2) 75 0.010
Need for maintenance
oral corticosteroids
(pharmacy data)
31 (33%)
n = 93
33 (34%)
n = 97
0 1.0
Required dose (mg) of
maintenance oral
corticosteroids
(pharmacy data)
10 (10) 10 (10) 0 0.684
Data are presented as n (%) or median (interquartile range).
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medication inhalation techniques, interactive patient education ses-
sions, psychosocial therapy sessions addressing disease manage-
ment skills, behavioral aspects of living with a chronic disease and
problems such as anxiety, stress, and depression and optional res-
piratory physiotherapy and dietary counselling. All patients were
provided with a personalized asthma action plan and instructed
how to step up treatment and when to consult their pulmonolo-
gist. The provided treatment program fits with the recently pro-
posed treatable traits for chronic airway disease and likely
contributed to the sustained asthma control during 12‐month fol-
low‐up.8 A subgroup of patients with a need for maintenance oral
steroids might benefit from phenotype specific monoclonal anti-
body therapy in the near future.
There are some inherent limitations to an observational study,
such as the lack of a control group with a similar program at sea
level. Our findings from a single center may have limited generaliz-
ability to other HACT centers. Furthermore, our study does not
provide insight to the possible mechanisms for the observed effect
during follow‐up, and biomarker data are lacking. The significant
differences on age and asthma control at discharge between the
patients who did and did not start follow‐up lead to bias in our
data. Therefore, our results should be interpreted with caution.
The beneficial effect of a 12‐week HACT in adults with severe
asthma can be predicted by different patient characteristics, such
as age, blood eosinophils, and degree of asthma control before
admission.9 Further patient characterization can help us to identify
the patients with long‐term advantage or more rapid deterioration
after HACT.
In conclusion, this study shows that HACT results in less exacer-
bations and sustained long‐term asthma control in patients with
uncontrolled severe asthma. HACT could be an adequate treatment
option for uncontrolled severe asthmatic patients besides all other
new treatment options, especially biologicals. Future trials and cost‐
effectiveness studies are needed to determine the best position for
HACT among all other treatment options.
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